AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39509231
Drug: Sertraline (pharmacotherapy)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (pharmacotherapy)
Trial: 39509708
Drug: MAL-ADL-PDT (160mg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL-ADL-PDT (160mg/g MAL cream)
Trial: 39509711
Drug: Xpert HR-CAD4TB
RxNorm normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xpert HR-CAD4TB [sequential negative]
Trial: 39509711
Drug: CRP-CAD4TB [sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP-CAD4TB [sequential negative]
Trial: 39509711
Drug: Xpert HR-CAD4TB
RxNorm normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xpert HR-CAD4TB [sequential positive]
Trial: 39510247
Drug: Blue light
RxNorm normalized name: Ocuvite Blue Light Mini Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue light exposure for 25 minutes daily for 5 or more days
Trial: 39510247
Drug: Red light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red light exposure for 25 minutes daily for 5 or more days (placebo)
Trial: 39510322
Drug: 5xICS (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5xICS (inhaled corticosteroids)
Trial: 39510322
Drug: 1xICS (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1xICS (inhaled corticosteroids)
Trial: 39510519
Drug: 12 mm
RxNorm normalized name: ReliOn Pen Needle 29g 12 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mm mini-implants
Trial: 39510519
Drug: 14 mm
RxNorm normalized name: human regenerative tissue mtrx 14 mm TOPICAL SHEET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mm mini-implants
Trial: 39510727
Drug: Iron-containing supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-containing supplements (mainly multivitamins) taken prepregnancy/early pregnancy
Trial: 39510727
Drug: Ferritin <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin < 60 μg/L
Trial: 39510727
Drug: Ferritin <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin < 15 μg/L
Trial: 39510727
Drug: Ferritin <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin < 30 μg/L
Trial: 39510727
Drug: sTfR >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sTfR > 4.4 mg/L
Trial: 39510727
Drug: TBI <
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TBI < 0 mg/kg
Trial: 39510769
Drug: Pharmacogenetic genotype-guided
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic genotype-guided statin prescription
Trial: 39510769
Drug: Standard-of-care statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care statin prescription
Trial: 39511164
Drug: benmelstobart (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benmelstobart (1200 mg) plus anlotinib (10 mg) plus paclitaxel (135 mg) for 4-6 cycles (21-day)
Trial: 39511164
Drug: benmelstobart (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benmelstobart (1200 mg) plus anlotinib (10 mg) plus chemotherapy
Trial: 39511203
Drug: EPA and
RxNorm normalized name: Norwegian Cod Liver Oil With EPA and DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA and DHA (2.7 g/day)
Trial: 39511203
Drug: EPA and
RxNorm normalized name: Norwegian Cod Liver Oil With EPA and DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA and DHA (dose-dependent)
Trial: 39511476
Drug: Dexmedetomidine (0.2-0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2-0.7 mcg/kg/h)
Trial: 39511611
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg/d) with standard of care concurrent chemoradiotherapy (cCRT)
Trial: 39511611
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care concurrent chemoradiotherapy (cCRT) without metformin
Trial: 39511631
Drug: Enhanced microeconomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced microeconomic intervention including 12 weekly educational group sessions, employment-focused mentoring, and an unconditional grant of US $1200.
Trial: 39512761
Drug: Quadrivalent standard-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent standard-dose, inactivated influenza vaccine (SD-IIV4)
Trial: 39513023
Drug: Subcutaneous alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous alemtuzumab (12 mg/day, total 60 mg)
Trial: 39513023
Drug: Intravenous alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous alemtuzumab (12 mg/day, total 36 mg)
Trial: 39513186
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus asunercept 400 mg
Trial: 39513186
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus asunercept 100 mg
Trial: 39513186
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus asunercept 25 mg
Trial: 39513267
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous BNP (0.005 µg/kg per minute)
Trial: 39513267
Drug: Combination BNP/PDEV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours
Trial: 39513363
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg p.o. daily with nivolumab 240 mg i.v. on days 1 and 15 of a 28-day cycle
Trial: 39513407
Drug: GLPG3970 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 350 mg + Sulfasalazine 1,000 mg
Trial: 39513407
Drug: GLPG3970 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 350 mg + Methotrexate 7.5 mg
Trial: 39513569
Drug: PEG-rhGH 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhGH 0.2 mg/kg/week (high dose)
Trial: 39513569
Drug: PEG-rhGH 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhGH 0.1 mg/kg/week (low dose)
Trial: 39514025
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg and 10 mg tamoxifen
Trial: 39514247
Drug: EHR-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHR-based medication alerts for DOAC prescriptions
Trial: 39514267
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg/m2) combined with chemotherapy and cryoablation
Trial: 39514431
Drug: Hybrid cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid cochlear implant with electric-acoustic stimulation (EAS)
Trial: 39514693
Drug: Hyponatremia (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyponatremia (sodium <135 mmol/L)
Trial: 39514693
Drug: Hypernatremia (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypernatremia (sodium >145 mmol/L)
Trial: 39514693
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate sodium (≤138 mmol/L)
Trial: 39514895
Drug: Facilitated initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Facilitated initiation of medications for AUD
Trial: 39515186
Drug: oVRcome mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oVRcome mobile application (self-managed virtual reality exposure therapy combined with cognitive-behavioural techniques)
Trial: 39515186
Drug: Waitlist delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist delayed treatment group
Trial: 39515361
Drug: Problem Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Management for Moms (PM4M) programme, a ten-session treatment offered by phone or in person.
Trial: 39515522
Drug: Concomitant eosinophil-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant eosinophil-lowering therapy
Trial: 39515580
Drug: Ultra-brief pulse
RxNorm normalized name: BRIEF,ULTRA BRIEF LARGE TENA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-brief pulse right unilateral Electroconvulsive Therapy (ECT)
Trial: 39515845
Drug: Online exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online exposure and response prevention behavioural therapy for tics
Trial: 39515856
Drug: Individual target
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual target transcranial magnetic stimulation (IT-TMS) combined with antidepressant medication
Trial: 39515867
Drug: Dexmedetomidine (0.4 µg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 µg/kg/h after anaesthesia induction until dural closure, then 0.08 µg/kg/h for 48 hours postoperatively)
Trial: 39515988
Drug: 40% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% dextrose gel
Trial: 39516358
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (Q28) with vandetanib 300 mg od (f + v)
Trial: 39516370
Drug: E7389-LF 2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7389-LF 2.1 mg/m plus nivolumab
Trial: 39516454
Drug: Risankizumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (150 mg, subcutaneous)
Trial: 39516710
Drug: fampridine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fampridine (10 mg twice daily for 3.5 days)
Trial: 39517110
Drug: Ritonavir-boosted atazanavir
RxNorm normalized name: atazanavir and ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted atazanavir (ATV/r) administered twice daily (BD)
Trial: 39518090
Drug: Quality Indicators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality Indicators in the Treatment of NMIBC
Trial: 39520634
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg as needed up to once daily for up to 52 weeks
Trial: 39520893
Drug: MenACWY-CRM (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (single dose)
Trial: 39521008
Drug: Concizumab prophylaxis
RxNorm normalized name: concizumab
DrugBank: Concizumab (DB12820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concizumab prophylaxis (1.0 mg/kg loading dose on day 1, followed by daily doses of 0.20 mg/kg, with options to adjust based on plasma concentration)
Trial: 39521433
Drug: Durvalumab 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 20 mg/kg every four weeks
Trial: 39521433
Drug: Chemotherapy every
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy every three weeks for four to six cycles
Trial: 39521460
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg buprenorphine maintenance daily dose
Trial: 39521460
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg buprenorphine maintenance daily dose
Trial: 39522018
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation intervention (8 tele-therapy sessions over 10 weeks)
Trial: 39522090
Drug: Alteplase (low-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (low- or high-dose) plus standard of care (SOC)
Trial: 39522541
Drug: Neoadjuvant toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant toripalimab (240 mg intravenously) every 2 weeks for two cycles followed by concurrent cisplatin (100 mg/m2)
Trial: 39522541
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with concurrent cisplatin (100 mg/m2)
Trial: 39522654
Drug: Amlitelimab 250
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlitelimab 250 mg every 4 weeks plus a 500-mg loading dose
Trial: 39522654
Drug: Amlitelimab 125
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlitelimab 125 mg every 4 weeks
Trial: 39522654
Drug: Amlitelimab 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlitelimab 62.5 mg every 4 weeks
Trial: 39522654
Drug: Amlitelimab (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlitelimab (any dose) continued for 28 weeks after initial treatment
Trial: 39522654
Drug: Amlitelimab (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlitelimab (any dose) stopped after initial treatment
Trial: 39522654
Drug: Amlitelimab (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlitelimab (any dose)
Trial: 39522824
Drug: eRT (FDG-PET-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eRT (FDG-PET-guided dose painting and scheduled adaptive radiotherapy)
Trial: 39522957
Drug: Baricitinib 4-mg
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4-mg equivalent
Trial: 39522957
Drug: Baricitinib 2-mg
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2-mg equivalent
Trial: 39522957
Drug: Baricitinib 1-mg
RxNorm normalized name: baricitinib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 1-mg equivalent
Trial: 39523543
Drug: Nirmatrelvir/ritonavir (NMV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirmatrelvir/ritonavir (NMV/r) 300 mg/100 mg every 12 hours for 5 days
Trial: 39523547
Drug: RSVpreF (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF (120 µg)
Trial: 39523681
Drug: Disease Severity
RxNorm normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease Severity Index (DSI) calculated from clearances of labelled cholates after oral and intravenous administration
Trial: 39523878
Drug: Three standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three standard doses of inactivated COVID-19 vaccines
Trial: 39523878
Drug: Two standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two standard doses plus a double dose of inactivated COVID-19 vaccines
Trial: 39523878
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of inactivated COVID-19 vaccines in healthy controls
Trial: 39524230
Drug: Acalabrutinib (monotherapy)
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acalabrutinib (monotherapy)
Trial: 39525672
Drug: PIKA COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIKA COVID-19 vaccine booster dose
Trial: 39525672
Drug: Inactivated COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated COVID-19 vaccine (Sinovac, China)
Trial: 39525677
Drug: PIKA-adjuvanted recombinant
RxNorm normalized name: varicella zoster virus glycoprotein E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (5 µg, 10 µg, and 20 µg)
Trial: 39525677
Drug: PIKA-adjuvanted recombinant
RxNorm normalized name: varicella zoster virus glycoprotein E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine
Trial: 39525887
Drug: Subcutaneous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tissue of lipedema stages I, II, and III
Trial: 39525887
Drug: Hypertrophied subcutaneous
RxNorm normalized name: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertrophied subcutaneous tissue
Trial: 39525940
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) using the Sanvello smartphone application for 4 weeks
Trial: 39526777
Drug: Abscess capsule
RxNorm normalized name: MYCOBACTERIUM ABSCESSUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abscess capsule FDG signal
Trial: 39526779
Drug: High-dose 5-ALA
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose 5-ALA (>40 mg/kg)
Trial: 39526779
Drug: Low/standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low/standard dose 5-ALA (<30 mg/kg)
Trial: 39526855
Drug: Low salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low salt diet (1.5 g/day) for 3 months
Trial: 39527056
Drug: Zoledronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (5 mg) in the first year
Trial: 39527056
Drug: Continuous denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous denosumab treatment (60 mg twice yearly)
Trial: 39527056
Drug: Zoledronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (5 mg) in the first year (ZOL subgroup with 3 or more years of denosumab treatment)
Trial: 39527097
Drug: Nivolumab, trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab, trastuzumab, and FOLFOX chemotherapy (FOLFOX arm)
Trial: 39527236
Drug: Upper Extremity
RxNorm normalized name: lymphedema garments, upper extremity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper Extremity Robotic Rehabilitation (RR) - ExoRehab X, Houston Bionics, twice/week for 6 weeks alongside conventional treatment.
Trial: 39527516
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) intervention over 4 weeks
Trial: 39528049
Drug: First Subsequent
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Subsequent Therapy (FST) with platinum-based chemotherapy and PARP inhibitor
Trial: 39528058
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg plus EGb 761 160 mg daily
Trial: 39528058
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg and clopidogrel 75 mg daily
Trial: 39528111
Drug: Solriamfetol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol (75 mg/d for 3 days, then 150 mg/d for 2 weeks)
Trial: 39528324
Drug: Tenofovir amibufenamide
RxNorm normalized name: Tenofovir amibufenamide
DrugBank: Tenofovir amibufenamide (DB18805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir amibufenamide therapy
Trial: 39528489
Drug: Isatuximab (Isa)
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab (Isa) 20-mg/kg administered weekly in cycle 1, then biweekly
Trial: 39528665
Drug: AUTO4 (TRBC1-directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUTO4 (TRBC1-directed autologous chimeric antigen receptor T cells)
Trial: 39529054
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of CAF/kg
Trial: 39529054
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of CAF/kg
Trial: 39529054
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg of CAF/kg
Trial: 39529169
Drug: Iparomlimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iparomlimab (200 mg or 3 mg/kg for patients with body weight < 40 kg, IV, Q3W) until disease progression, intolerable toxicities, withdrawal of consent, death, or up to 2 years.
Trial: 39529175
Drug: Collaboration strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaboration strategies (e.g., staff co-location, communication quality)
Trial: 39529199
Drug: Intermittent theta
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex (LDLPFC) once daily for 10 consecutive workdays, with parameters of 120% resting motor threshold, 50 Hz bursts repeated at 5 Hz, 600 pulses per session (total duration 3 min 9 s)
Trial: 39529482
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg/kg over 10 min, followed by 0.4 μg/kg/h continuous infusion)
Trial: 39529939
Drug: High-dose multistrain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multistrain probiotic mix (Sinquanon)
Trial: 39530465
Drug: Personalized nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized nutrition and exercise intervention (high-protein diet with daily protein supplementation, functional training with strength and aerobic exercises)
Trial: 39530558
Drug: Nivolumab 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 480 mg intravenously every 4 weeks up to 6 months
Trial: 39530574
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab vedotin 1.25 mg/kg (Days 1, 8, and 15)
Trial: 39530627
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tarlatamab
Trial: 39530627
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tarlatamab